AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21241207
Drug: Infliximab 5
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab 5 mg/kg every 12 weeks (q12w)
Trial: 21241207
Drug: Infliximab 10
RxNorm normalized name: infliximab 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab 10 mg/kg every 8 weeks (q8w)
Trial: 17434171
Drug: Aspirin 500
RxNorm normalized name: aspirin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 500 mg pre-treatment
Trial: 17434171
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no addition of 500 mg aspirin)
Trial: 10233210
Drug: Nabumetone (1-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nabumetone (1-2 g daily for up to 4 weeks)
Trial: 1781870
Drug: Zidovudine (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine (1000 mg/day) or placebo
Trial: 7552477
Drug: Zidovudine (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine (500 mg/day)
Trial: 1781870
Drug: CD4+ counts
RxNorm normalized name: oteseconazole
DrugBank: Oteseconazole (DB13055)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CD4+ counts less than or equal to 0.2 x 10(9)/l before 30 November 1988
Trial: 7082523
Drug: Midazolam 0.2
RxNorm normalized name: midazolam 0.2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.2 mg kg‐1
Trial: 7082523
Drug: Thiopentone 3
RxNorm normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiopentone 3 mg kg‐1
Trial: 21543293
Drug: Carvedilol 25
RxNorm normalized name: carvedilol 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol 25 mg once daily for one month
Trial: 21543293
Drug: Nebivolol 5
RxNorm normalized name: nebivolol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol 5 mg once daily for one month
Trial: 18481715
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment at specific acupoints (contralateral scalp motor region, Jiquan (HT 1), Chize (LU 5), Daling (PC 7), Jianyu (LI 15), Tianjing (TE 10), Yangchi (TE 4)) for 3 weeks.
Trial: 18481715
Drug: Electro-stimulation treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electro-stimulation treatment for 3 weeks.
Trial: 29660924
Drug: Fluid restrictive
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid restrictive regimen with norepinephrine administration up to 0.04μg/kg/min (FRV)
Trial: 29660924
Drug: Liberal fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liberal fluid administration (LFA)
Trial: 24941835
Drug: Yupingfeng Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yupingfeng Powder (YP) combined with routine treatment (inhaled corticosteroids and/or leukotriene regulator)
Trial: 24941835
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment (inhaled corticosteroids and/or leukotriene regulator)
Trial: 15968840
Drug: Functional cognitive-behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional cognitive-behavioural therapy (FCBT)
Trial: 10594471
Drug: SDZ RAD
RxNorm normalized name: RAD-IFN
DrugBank: Nadofaragene firadenovec (DB17381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SDZ RAD (0.25, 0.75, 2.5, 7.5, 15, 25 mg)
Trial: 10594471
Drug: SDZ RAD
RxNorm normalized name: RAD-IFN
DrugBank: Nadofaragene firadenovec (DB17381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SDZ RAD (2.5-25 mg)
Trial: 10594471
Drug: SDZ RAD
RxNorm normalized name: RAD-IFN
DrugBank: Nadofaragene firadenovec (DB17381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SDZ RAD (0.25-25 mg)
Trial: 2011703
Drug: Diet and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet and Senna laxative (X‐prep) combined with a saline enema (n = 88)
Trial: 2011703
Drug: Polyethylene glycol
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyethylene glycol electrolyte lavage solution (Golytely) (n = 90)
Trial: 2011703
Drug: Combined regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined regimen of Cascara‐Salax laxative (PicoSalax) and Golytely (n = 93)
Trial: 7073570
Drug: Topical indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical indomethacin administration before and after surgery
Trial: 25759942
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (reflection seminars)
Trial: 22759866
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg levobupivacaine (group L)
Trial: 22759866
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg tramadol (group T)
Trial: 22759866
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg tramadol plus 100 mg levobupivacaine (group LT)
Trial: 11505416
Drug: TRAUMEEL S
RxNorm normalized name: Traumeel S Injection Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRAUMEEL S (mouth rinse, 5 times daily for a minimum of 14 days)
Trial: 11505416
Drug: Placebo (mouth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (mouth rinse, 5 times daily for a minimum of 14 days)
Trial: 9052357
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and ticlopidine pretreatment
Trial: 19781416
Drug: Early abciximab
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early abciximab administration (EA) in high-risk patients (n = 413)
Trial: 19781416
Drug: Late abciximab
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Late abciximab administration (LA) in high-risk patients (n = 203)
Trial: 19781416
Drug: Early abciximab
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early abciximab administration (EA) in low-risk patients (n = 314)
Trial: 19781416
Drug: Late abciximab
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Late abciximab administration (LA) in low-risk patients (n = 156)
Trial: 16407020
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate solution
Trial: 11237929
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (1 g EPA plus DHA daily, containing 720 mg EPA + 280 mg DHA)
Trial: 11237929
Drug: ALA (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALA (2 g daily)
Trial: 11237929
Drug: GLA (770
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLA (770 mg daily)
Trial: 11237929
Drug: AA (680
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AA (680 mg daily)
Trial: 11237929
Drug: DHA (720
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA (720 mg daily)
Trial: 8986685
Drug: Transdermal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal administration of 100 micrograms/d E2
Trial: 8362228
Drug: Erythromycin treatment
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin treatment for 7 days
Trial: 3496948
Drug: Dipyridamole (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyridamole (120 mg/d) by constant intravenous infusion
Trial: 3496948
Drug: Isotonic dextrose
RxNorm normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic dextrose solution
Trial: 30508890
Drug: Protocol A
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol A (90 kVp/395 mAs, contrast agent dosage of 1.2 mL/kg)
Trial: 30508890
Drug: Protocol B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol B (120 kVp/200 mAs, contrast agent dosage of 1.5 mL/kg)
Trial: 21357965
Drug: Standard Ponseti
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Ponseti method (plaster change weekly)
Trial: 18070980
Drug: Levofloxacin, 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin, 1,000 mg daily
Trial: 18070980
Drug: Gatifloxacin, 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gatifloxacin, 400 mg daily
Trial: 18070980
Drug: Moxifloxacin, 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin, 400 mg daily
Trial: 14679153
Drug: CMF chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMF chemotherapy (n = 360)
Trial: 14679153
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy (CMF -> goserelin)
Trial: 14679153
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (for ER-positive patients)
Trial: 11127233
Drug: Insecticide-treated nets
RxNorm normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insecticide-treated nets (ITNs) with permethrin, 0.5 g/m2
Trial: 11127233
Drug: Insecticide-treated chaddars
RxNorm normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insecticide-treated chaddars with permethrin, 1 g/m2
Trial: 11127233
Drug: Residual spraying
RxNorm normalized name: antihemophilic factor, human recombinant residues 743-1636 deleted Injection [Xyntha]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Residual spraying of houses with lambdacyhalothrin, 30 mg/m2
Trial: 949903
Drug: 0.05% clobetasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% clobetasone butyrate cream or ointment
Trial: 949903
Drug: 0.0125% flurandrenolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.0125% flurandrenolone cream or ointment
Trial: 27790789
Drug: Simeprevir 150
RxNorm normalized name: simeprevir 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simeprevir 150 mg and sofosbuvir 400 mg daily for 8 weeks (Group A1, n=20)
Trial: 27790789
Drug: Simeprevir 150
RxNorm normalized name: simeprevir 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simeprevir 150 mg and sofosbuvir 400 mg daily for 12 weeks (Group A2, n=20)
Trial: 27790789
Drug: Simeprevir 150
RxNorm normalized name: simeprevir 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simeprevir 150 mg and sofosbuvir 400 mg daily for 12 weeks (Group B, n=23)
Trial: 25985992
Drug: Mass Testing
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mass Testing and Treatment Intervention (MTAT) using rapid diagnostic tests (RDTs) and artemether-lumefantrine (AL)
Trial: 25985992
Drug: No Mass
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No Mass Testing and Treatment Intervention (Standard of Care)
Trial: 22594858
Drug: Meglumine antimoniate
RxNorm normalized name: meglumine antimoniate
DrugBank: Meglumine antimoniate (DB13732)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meglumine antimoniate (20 mg Sb5/kg weight/day for 20 days)
Trial: 17223022
Drug: Bioadhesive formulations
RxNorm normalized name: urea
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bioadhesive formulations (LM-5, LM-12, chitosan G210) delivered using a nasal drop device
Trial: 17223022
Drug: Pectin formulation
RxNorm normalized name: Pectin
DrugBank: Pectin (DB11158)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pectin formulation administered with a nasal spray system
Trial: 17223022
Drug: Bioadhesive formulations
RxNorm normalized name: urea
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bioadhesive formulations
Trial: 12401244
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulphate (2 g bolus over 15 min, followed by 17 g infusion over 24 h)
Trial: 9649951
Drug: Insulin +
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin + Glipizide (I + G)
Trial: 9649951
Drug: Insulin +
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin + Placebo (I + P)
Trial: 1962618
Drug: Nizatidine 300
RxNorm normalized name: nizatidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nizatidine 300 mg hs
Trial: 7236871
Drug: Propranolol 5
RxNorm normalized name: propranolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 5 mg
Trial: 7236871
Drug: Propranolol 20-640
RxNorm normalized name: propranolol 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 20-640 mg d-1
Trial: 7236871
Drug: Propranolol (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (various doses)
Trial: 29121979
Drug: Ticagrelor plus
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor plus Aspirin (TIC + ASP) for 4 weeks
Trial: 29121979
Drug: Ticagrelor plus
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor plus Aspirin (TIC + ASP)
Trial: 21251179
Drug: LY2189265 (LY)
RxNorm normalized name: LYS
DrugBank: Lysine (DB00123)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: LY2189265 (LY) 0.1 to 12 mg, single escalating subcutaneous injections
Trial: 21251179
Drug: LY2189265 (LY)
RxNorm normalized name: LYS
DrugBank: Lysine (DB00123)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: LY2189265 (LY) doses ≥1.0 mg
Trial: 21251179
Drug: LY2189265 (LY)
RxNorm normalized name: LYS
DrugBank: Lysine (DB00123)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: LY2189265 (LY) doses ≥3.0 mg
Trial: 17593957
Drug: Gatifloxacin 10
RxNorm normalized name: GATIFLOXACIN 10MG/ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gatifloxacin 10 mg/kg, given once daily for 7 days
Trial: 17593957
Drug: Cefixime 20
RxNorm normalized name: cefixime 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefixime 20 mg/kg/day given in two divided doses for 7 days
Trial: 15034229
Drug: Climodien 2/3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Climodien 2/3 (estradiol valerate 2 mg + dienogest 3 mg)
Trial: 11511790
Drug: 100 ml
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml of 20% human albumin followed by 160 mg of furosemide
Trial: 11511790
Drug: Sham solution
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham solution followed by 160 mg of furosemide
Trial: 7516361
Drug: Total paracentesis
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total paracentesis with dextran‐40 infusion (8 g per liter of ascitic fluid removed)
Trial: 7516361
Drug: Total paracentesis
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total paracentesis with dextran‐40 infusion
Trial: 2735337
Drug: Sucralfate (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate (1 g four times per day)
Trial: 2660562
Drug: Ranitidine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (150 mg twice per day)
Trial: 21843831
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (usual daily activities)
Trial: 24032226
Drug: Combined systemic
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined systemic and regional chemotherapy
Trial: 17002935
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E supplementation; specific dosage and duration not available
Trial: 14586909
Drug: Conventional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physical therapy with resistance
Trial: 8267700
Drug: Maintenance resistance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance resistance training twice a week
Trial: 4035232
Drug: Pentoxifylline (PTX)
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (PTX) alone or associated with conventional antihypertensive therapy
Trial: 30021886
Drug: Anti-CTLA-4 therapy
RxNorm normalized name: INVESTIGATIONAL ANTI-NEOPLASTIC DRUGS, GENE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-CTLA-4 therapy
Trial: 30021886
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (anti-CTLA-4 and anti-PD-1)
Trial: 30650288
Drug: Xinfeng Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xinfeng Capsule (XFC), 3 pills each time, 3 times per day for 3 months
Trial: 30641625
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (HCQ) Sulfate, 0.1 g per tablet, 2 tablets each time, twice per day for 3 months
Trial: 22740509
Drug: Metformin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (2 g/day for 4 months)
Trial: 20173020
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) treatment (1 mg/m²·d) for 12 and 24 months
Trial: 17908978
Drug: LT plus
RxNorm normalized name: BALANCED SALT PLUS SOLN,OPH IRRG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LT plus ADV‐TK therapy
Trial: 17908978
Drug: LT plus
RxNorm normalized name: BALANCED SALT PLUS SOLN,OPH IRRG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LT plus ADV‐TK therapy (nonvascular invasion subgroup)
Trial: 15796730
Drug: Intravenous antivenom
RxNorm normalized name: ANTIVENIN,CROTALIDAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous antivenom (AV)
Trial: 15796730
Drug: Intramuscular antivenom
RxNorm normalized name: ANTIVENIN,CROTALIDAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular antivenom (AV)
Trial: 12443837
Drug: Ospemifene 25
RxNorm normalized name: Ospemifene
DrugBank: Ospemifene (DB04938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ospemifene 25 mg
Trial: 12443837
Drug: Ospemifene 50
RxNorm normalized name: Ospemifene
DrugBank: Ospemifene (DB04938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ospemifene 50 mg
Trial: 12443837
Drug: Ospemifene 100
RxNorm normalized name: Ospemifene
DrugBank: Ospemifene (DB04938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ospemifene 100 mg
Trial: 12443837
Drug: Ospemifene 200
RxNorm normalized name: Ospemifene
DrugBank: Ospemifene (DB04938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ospemifene 200 mg
Trial: 9860407
Drug: Interferon-alpha-2b (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-alpha-2b (3 MU thrice weekly) and ribavirin (1000-1200 mg/daily per os) for 24 weeks
Trial: 9860407
Drug: Interferon-alpha-2b alone
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha-2b alone (6 MU thrice weekly) for 24 weeks
Trial: 27422421
Drug: Intralesional corticosteroid
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional corticosteroid injection (40 mg methylprednisolone) at monthly intervals for 6 consecutive months
Trial: 23060056
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical care plus chiropractic manipulative therapy (CMT)
Trial: 21903774
Drug: CYP3A4 CC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYP3A4 CC homozygotes plus CYP3A5*3/*3
Trial: 21903774
Drug: CYP3A4 CC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYP3A4 CC homozygotes with CYP3A5*3/*3
Trial: 21903774
Drug: CYP3A4 CC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYP3A4 CC homozygotes with CYP3A5*1
Trial: 18582308
Drug: 15 mg/ml
RxNorm normalized name: phenol 15 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/ml hyperbaric lidocaine
Trial: 18582308
Drug: 20 mg/ml
RxNorm normalized name: urea 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/ml hyperbaric lidocaine
Trial: 12862201
Drug: Candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Candesartan cilexetil 4 mg daily (candesartan group)
Trial: 9346162
Drug: Carbohydrate supplement
RxNorm normalized name: carbohydrate supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate supplement (N = 17)
Trial: 2420164
Drug: Ethmozine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethmozine (10 mg/kg/day)
Trial: 2420164
Drug: Ethmozine (maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethmozine (maintenance therapy)
Trial: 19243745
Drug: P along
RxNorm normalized name: P & S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P along with 6 mg E(2) valerate vaginally (group C)
Trial: 19243745
Drug: P along
RxNorm normalized name: P & S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P along with 6 mg E(2) valerate orally (group B)